Welcome to our dedicated page for Mediwound SEC filings (Ticker: MDWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MediWound Ltd. (MDWD) SEC filings page brings together the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. MediWound files reports on Form 6-K to furnish press releases, financial statements, and transaction details, and uses shelf registration statements on Form F-3 and employee share plans on Form S-8 for capital markets activities. These documents provide structured insight into the company’s biotechnology business focused on enzymatic, non-surgical therapies for tissue repair.
In its Form 6-K filings, MediWound furnishes quarterly and interim financial results, including condensed consolidated statements of financial position and profit or loss, along with management press releases discussing revenue, operating loss, cash balances, and non-IFRS measures such as Adjusted EBITDA. Other 6-Ks describe registered direct offerings of ordinary shares under an effective Form F-3 shelf registration statement, including purchase agreements, use of proceeds for EscharEx® pre-commercial activities and manufacturing expansion, and related legal opinions.
Filings also reference government-supported programs and contracts that are important to MediWound’s burn and chronic wound portfolio. BARDA- and U.S. Department of Defense-funded projects for NexoBrid®, including clinical development, regulatory submissions, emergency procurement, and formulation work, are discussed in the company’s press releases that are incorporated by reference into SEC reports. Insider share purchases by senior leadership are reported on Form 6-K, providing transparency into management’s trading activity.
On Stock Titan, these SEC filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain key points from lengthy filings, highlight changes in financial condition, and surface important details about offerings, grants, and clinical or manufacturing milestones. Users can quickly locate quarterly updates, registration statements, and reports that reference NexoBrid and EscharEx, and review how MediWound describes its risks, funding, and strategic priorities over time.
Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon and Gilad Aharon report beneficial ownership of 570,326 MediWound common shares, representing 5.2% of outstanding shares based on 10,793,057 shares. The position comprises 407,061 issued common shares and 163,265 shares issuable upon exercise of warrants. Each reporting person discloses shared voting and dispositive power over 407,061 shares and no sole voting or dispositive power. The reported warrants contain a blocker provision preventing exercise to the extent such exercise would raise beneficial ownership above 9.99%. The advisor and Mr. Salamon disclaim beneficial ownership of shares held by the fund.